TrialHaematologica2018

Benefits and pitfalls of pegylated interferon-α2a therapy in patients with myeloproliferative neoplasm-associated myelofibrosis: a French Intergroup of Myeloproliferative neoplasms (FIM) study.

Jean-Christophe Ianotto et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.